---
figid: PMC3621026__nihms429472f1a
figlink: /pmc/articles/PMC149053/figure/fig7/
number: F1a
caption: Pharmacological strategies to overcome resistance to apoptosis in cancer
  cells treated with PI3K/mTOR inhibitors. (A) Many tumor cells have activated receptor
  tyrosine kinases (RTKs), or cytoplasmic tyrosine kinases, and/or activation of the
  RAS/RAF/MEK/ERK pathway. Combining TKIs or MEK inhibitors with PI3K/mTOR inhibitors
  can induce cancer cell death. (B) Pro-apoptotic genes are often silenced epigenetically
  in tumor cells. HDAC inhibition leads to increased histone acetylation and more
  open chromatin state at gene regulatory elements. PI3K/mTOR inhibition triggers
  nuclear accumulation of FOXO transcription factors, which can access pro-apoptotic
  gene promoters when cells are treated with HDAC inhibitors. (C) Low mitochondrial
  priming is a significant barrier to apoptotic induction in some cancer cells. BCL2
  antagonists can increase priming and lower the threshold for apoptotic induction
  by PI3K/mTOR inhibitors.
pmcid: PMC3621026
papertitle: Achieving cancer cell death with PI3K/mTOR-targeted therapies.
reftext: Sung Su Yea, et al. Ann N Y Acad Sci. ;1280(1):15-18.
pmc_ranked_result_index: '31374'
pathway_score: 0.9718213
filename: nihms429472f1a.jpg
figtitle: Achieving cancer cell death with PI3K/mTOR-targeted therapies
year: ''
organisms:
- Homo sapiens
ndex: 8fd2adb2-debf-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3621026__nihms429472f1a.html
  '@type': Dataset
  description: Pharmacological strategies to overcome resistance to apoptosis in cancer
    cells treated with PI3K/mTOR inhibitors. (A) Many tumor cells have activated receptor
    tyrosine kinases (RTKs), or cytoplasmic tyrosine kinases, and/or activation of
    the RAS/RAF/MEK/ERK pathway. Combining TKIs or MEK inhibitors with PI3K/mTOR inhibitors
    can induce cancer cell death. (B) Pro-apoptotic genes are often silenced epigenetically
    in tumor cells. HDAC inhibition leads to increased histone acetylation and more
    open chromatin state at gene regulatory elements. PI3K/mTOR inhibition triggers
    nuclear accumulation of FOXO transcription factors, which can access pro-apoptotic
    gene promoters when cells are treated with HDAC inhibitors. (C) Low mitochondrial
    priming is a significant barrier to apoptotic induction in some cancer cells.
    BCL2 antagonists can increase priming and lower the threshold for apoptotic induction
    by PI3K/mTOR inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R6
  - PDK1
  - KRAS
  - MAPK1
  - MAP2K2
  - MAP2K1
  - BRAF
  - MAPK3
  - HRAS
  - PIK3R3
  - AKT3
  - CRTC2
  - PIK3CG
  - PIK3CB
  - RAF1
  - NRAS
  - PIK3CA
  - CRTC1
  - PIK3CD
  - AKT1
  - PIK3R5
  - AKT2
  - ARAF
  - PIK3R4
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: TORC2
  symbol: TORC2
  source: hgnc_alias_symbol
  hgnc_symbol: CRTC2
  entrez: '200186'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: TORC1
  symbol: TORC1
  source: hgnc_alias_symbol
  hgnc_symbol: CRTC1
  entrez: '23373'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3621026__F1a
redirect_from: /figures/PMC3621026__F1a
figtype: Figure
---
